子宫内膜异位症与卵巢癌:流行病学、分子机制与临床决策
本文综述子宫内膜异位症(尤其卵巢子宫内膜瘤)与卵巢癌的关系:后者风险约增加2倍,以透明细胞癌和子宫内膜样亚型为主,但终生绝对风险仍较低(约1.9%)。文中汇总ARID1A、PIK3CA、KRAS体细胞突变等分子联系,并讨论影像、生物标志物、激素治疗与手术在风险管理中的价值。
要点
- 子宫内膜异位症相关卵巢癌风险约增2倍,但终生绝对风险约1.9%。
- 长期使用复方口服避孕药可降低卵巢癌风险,停药后保护持续十余年。
- 预防性输卵管卵巢切除仅推荐用于已知遗传易感者,不常规用于单纯子宫内膜异位症。
核心结论
- 子宫内膜异位症与卵巢癌的关联已明确,但治疗策略需在癌症预防、生育力保护与生活质量间个体化平衡。
研究设计与样本
- 本文为叙述性综述,围绕流行病学数据、分子联系、诊断进展与临床管理进行聚焦概述。
主要发现
- 子宫内膜异位症尤其卵巢子宫内膜瘤与卵巢癌风险约增加2倍相关,以透明细胞癌和子宫内膜样亚型为主。
- 子宫内膜异位症女性卵巢癌终生绝对风险仍相对较低,估计为1.9%。
- ARID1A、PIK3CA和KRAS体细胞突变在子宫内膜异位症与某些卵巢癌亚型间共享。
- 经阴道超声和MRI提高了子宫内膜异位症诊断,但识别恶变仍不可靠。
- CA-125和HE4可提供额外诊断信息,但特异性低限制其临床作用。
关键数值与推荐
- 长期使用复方口服避孕药可显著降低子宫内膜异位症女性的卵巢癌风险,保护作用停药后持续十余年,风险低于一般人群。
- 复方口服避孕药还与子宫内膜癌和结直肠癌的保护作用相关。
- 卵巢子宫内膜瘤切除可能提供卵巢癌保护,但需权衡复发与卵巢储备损失风险,尤其年轻女性。
- 已知遗传易感女性推荐预防性输卵管卵巢切除,单纯子宫内膜异位症者不常规推荐。
临床怎么用
- 对子宫内膜异位症女性应个体化评估卵巢癌风险,长期复方口服避孕药可用于降低风险并兼具其他癌症保护。
- 手术决策需综合生育需求、复发风险与卵巢储备,年轻女性尤其谨慎。
- 推动纳入遗传、临床与环境因素的个体化风险预测模型,并采用多学科方法管理。
局限性
- 需长期研究评估保守与手术管理对卵巢癌风险和总生存的影响。
- 影像与生物标志物对恶变识别可靠性不足,CA-125和HE4特异性低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Endometriosis, particularly ovarian endometrioma, is associated with a 2-fold increased risk of ovarian cancer (OC), especially the clear cell and endometrioid subtypes. However, the absolute lifetime risk of OC in women with endometriosis remains relatively low, estimated at 1.9%. This review provides a focused overview of the relationship between these two conditions, addressing epidemiologic data, molecular links, advances in diagnosis, and clinical management. Somatic mutations in ARID1A, PIK3CA, and KRAS are shared between endometriosis and certain OC subtypes, and the nature of the environment typical of ovarian endometriomas suggests a context-specific oncogenic journey. Although advances in imaging, like transvaginal ultrasound and MRI, have improved endometriosis diagnosis, these modalities remain unreliable for identifying malignant transformation. Biomarkers, including CA-125 and HE4, provide additional diagnostic information, although their low specificity limits their role in clinical practice. Hormonal therapies, particularly the long-term use of combined oral contraceptives (COCs), have proven to be highly effective in reducing OC risk in women with endometriosis. This protective effect persists for more than a decade after discontinuation and has been associated with a risk lower than that of the general population. In addition, COC use has been linked to further protective effects against endometrial and colorectal cancers, highlighting its potential value as a cancer prevention strategy, especially for high-risk groups. Surgical management, particularly the excision of ovarian endometriomas, may also confer protection against OC, although this must be balanced against the risks of recurrence and ovarian reserve loss, especially in younger women. Prophylactic salpingo-oophorectomy is recommended for women with known genetic predispositions, but is not routinely indicated for those with endometriosis alone. Emerging evidence highlights the need for personalized risk prediction models that incorporate genetic, clinical, and environmental factors to guide care. Long-term studies are required to assess the impact of conservative versus surgical management on OC risk and overall survival. This review emphasizes the importance of a multidisciplinary approach to the management of endometriosis in relation to OC risk. While the link between endometriosis and OC is well-established, treatment strategies must be tailored to balance cancer prevention, fertility preservation, and quality of life.
引用
- Leone Roberti Maggiore U, Vignali M, Kvaskoff M, et al. Endometriosis and ovarian cancer: epidemiological evidence, molecular insights, and clinical decision-making. Hum Reprod Update. 2026. PMID: 42143676. doi:10.1093/humupd/dmag011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。